PET in brain tumors
- 89 Downloads
The aim of this Pictorial Essay is to illustrate the metabolic aspect of PET (positron emission tomography) imaging in relation to conventional and advanced MR (magnetic resonance) of brain neoplasms.
10 patients, who performed PET–CT with amino acid tracers and/or FDG were selected from a series of more than 250 cases from a single institution. The selection was made to illustrate and discuss each of the indications reported in the European guidelines. Fusion imaging was obtained merging PET–CT with MR T1-CE (contrast enhanced) and/or T2/FLAIR sequences. The SUVmax of the lesion and the SUVmax lesion to SUVmax background ratio were evaluated. The lesion uptake was also assessed using a five-point visual scale with a range from − 2 to + 2 in relation to basal ganglia uptake. The Hospital Information System (HIS) and the proton therapy data archives have been used for clinical history. For each case, the critical issues were described and the physiopathological correlations were provided to explain the imaging findings.
The complexity of illustrated cases demonstrates the need for a multidisciplinary board evaluation to reach a more accurate diagnosis.
KeywordsBrain lesions Differential diagnosis PET–CT imaging Advanced MR
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Linee Guida delle Neoplasie Cerebrali. AIOM (Associazione Italiana Oncologia Medica) Edizione 2017Google Scholar
- 3.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol. https://doi.org/10.1007/s00401-016-1545-1 Google Scholar
- 6.Thust SC, Heiland S, Falini A, Jäger HR, Waldman AD, Sundgren PC, Godi C, Katsaros VK, Ramos A, Bargallo N, Vernooij MW, Yousry T, Bendszus M, Smits M (2018) Glioma imaging in Europe: a survey of 220 centres and recommendations for best clinical practice. Eur Radiol 28(8):3306–3317PubMedGoogle Scholar
- 7.Pyka T, Gempt J, Bette S, Ringel F, Förster S (2017) Positron emission tomography and magnetic resonance spectroscopy in cerebral gliomas. Clin Transl Imaging 5(2):151–158Google Scholar
- 10.A joint RANO/EANO/EANM practice guideline/SNMMI procedure standard for imaging of gliomas using PET with radiolabeled amino acids and [18F]FDG: version 1.0Google Scholar
- 12.Oehlke O, Grosu AL (2016) A-L.PET/MRI and brain tumors: focus on radiation oncology treatment planning. Clin Transl Imaging 2(5):159–167Google Scholar
- 13.Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18:1199–1208PubMedGoogle Scholar
- 19.Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH (2013) Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radio- therapy target delineation: results of a prospective pilot study. Neuro Oncol 15(8):1058–1067PubMedGoogle Scholar
- 20.Takahashi Y, Akahane T, Yamamoto D, Nakamura H, Sawa H, Nitta K, Ide W, Hashimoto I, Kamada H (2014) Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas. Mol Clin Oncol 2:525–529PubMedGoogle Scholar
- 24.Dadone-Montaudié B, Ambrosetti D, Dufour M, Darcourt J, Almairac F, Coyne J, Virolle T, Humbert O, Burel-Vandenbros F (2017) [18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression. PLoS One 22 12(9):e0184625. https://doi.org/10.1371/journal.pone.0184625 Google Scholar
- 25.Freyschlag CF, Krieg SM, Kerschbaumer J, Pinggera D, Forster MT, Cordier D, Rossi M, Miceli G, Roux A, Reyes A, Sarubbo S, Smits A, Sierpowska J, Robe PA, Rutten GJ, Santarius T, Matys T, Zanello M, Almairac F, Mondot L, Jakola AS, Zetterling M, Rofes A, von Campe G, Guillevin R, Bagatto D, Lubrano V, Rapp M, Goodden J, De Witt Hamer PC, Pallud J, Bello L, Thomé C, Duffau H, Mandonnet E (2018) Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging. J Neurooncol 139:699–711. https://doi.org/10.1007/s11060-018-2916-3 PubMedGoogle Scholar
- 32.Toch SR, Poussier S, Micard E, Bertaux M, Van Der Gucht A, Chevalier E, Marie PY, Guedj E, Verger A (2018) Physiological whole-brain distribution of [18F]FDOPA uptake index in relation to age and gender: results from a voxel-based semi-quantitative analysis. Mol Imaging Biol. https://doi.org/10.1007/s11307-018-1256-1 PubMedGoogle Scholar
- 34.Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AAF, Yong WH, Phelps ME, Chen W (2014) 18F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med 55:1–7Google Scholar